Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Pande, A. C. Articles by Liu-Dumaw, M. Search for Related Content PubMed Citation Articles by Pande, A. C. Articles by Liu-Dumaw, M. Anxiety Disorders (General) Anxiolytics

Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial

OBJECTIVE: Current drug therapies for generalized anxiety disorder have limitations. In a controlled trial, the novel agent pregabalin was studied for the treatment of patients with generalized anxiety disorder. METHOD: In this double-blind study, patients with DSM-IV generalized anxiety disorder were randomly assigned to receive pregabalin (150 mg/day or 600 mg/day), lorazepam (6 mg/day), or placebo. A 1-week placebo lead-in was followed by 4 weeks of treatment and then a 1-week dose taper. The primary efficacy measure was the Hamilton Anxiety Rating Scale score at endpoint. RESULTS: A total of 276 patients were randomly assigned to a treatment group and received at least one dose of their assigned medication. Fewer patients given lorazepam (59%, N=40 of 68) completed the trial than did those given placebo (73%, N=50 of 69), 600 mg/day of pregabalin (71%, N=50 of 70), or 150 mg/day or pregabalin (90%, N=62 of 69). The mean baseline-to-endpoint decreases in total Hamilton anxiety scale score in the patients given 150 mg/day of pregabalin (–9.2), 600 mg/day of pregabalin (–10.3), and lorazepam (–12.0) were significantly greater than the decrease in those given placebo (–6.8). As early as the week 1 observation, pregabalin significantly reduced the total Hamilton anxiety scale score compared with placebo. The most frequent adverse events reported for pregabalin and lorazepam were somnolence and dizziness. There were no serious adverse events reported by patients given pregabalin, and no withdrawal syndrome was associated with pregabalin treatment. CONCLUSIONS: These results indicate that pregabalin is an effective, rapidly acting, and safe treatment for generalized anxiety disorder. In short-term treatment, pregabalin does not appear to have the withdrawal symptoms associated with the benzodiazepines.

This article has been cited by other articles:

				N. M. Gajraj Pregabalin: Its Pharmacology and Use in Pain Management Anesth. Analg., December 1, 2007; 105(6): 1805 - 1815. [Abstract] [Full Text] [PDF]

				R. B. Hidalgo, L. A. Tupler, and J. R. T. Davidson An effect-size analysis of pharmacologic treatments for generalized anxiety disorder J Psychopharmacol, November 1, 2007; 21(8): 864 - 872. [Abstract] [PDF]

				M. Showraki Pregabalin in the treatment of depression J Psychopharmacol, November 1, 2007; 21(8): 883 - 884. [Abstract] [PDF]

				H. C. BECKER, H. MYRICK, and L. M. VEATCH PREGABALIN IS EFFECTIVE AGAINST BEHAVIORAL AND ELECTROGRAPHIC SEIZURES DURING ALCOHOL WITHDRAWAL Alcohol Alcohol., July 1, 2006; 41(4): 399 - 406. [Abstract] [Full Text] [PDF]

				S. J. Mathew, J. M. Amiel, J. D. Coplan, H. A. Fitterling, H. A. Sackeim, and J. M. Gorman Open-Label Trial of Riluzole in Generalized Anxiety Disorder Am J Psychiatry, December 1, 2005; 162(12): 2379 - 2381. [Abstract] [Full Text] [PDF]

				B. F Shneker and J. W McAuley Pregabalin: A New Neuromodulator with Broad Therapeutic Indications Ann. Pharmacother., December 1, 2005; 39(12): 2029 - 2037. [Abstract] [Full Text] [PDF]

				K. Rickels, M. H. Pollack, D. E. Feltner, R. B. Lydiard, D. L. Zimbroff, R. J. Bielski, K. Tobias, J. D. Brock, G. L. Zornberg, and A. C. Pande Pregabalin for Treatment of Generalized Anxiety Disorder: A 4-Week, Multicenter, Double-blind, Placebo-Controlled Trial of Pregabalin and Alprazolam Arch Gen Psychiatry, September 1, 2005; 62(9): 1022 - 1030. [Abstract] [Full Text] [PDF]

				A. Lippa, P. Czobor, J. Stark, B. Beer, E. Kostakis, M. Gravielle, S. Bandyopadhyay, S. J. Russek, T. T. Gibbs, D. H. Farb, et al. Selective anxiolysis produced by ocinaplon, a GABAA receptor modulator PNAS, May 17, 2005; 102(20): 7380 - 7385. [Abstract] [Full Text] [PDF]

				E. A. Hoge, J. E. Oppenheimer, and N. M. Simon Generalized Anxiety Disorder Focus, July 1, 2004; 2(3): 346 - 359. [Full Text] [PDF]

				R. Pary High dose pregabalin is effective for the treatment of generalised anxiety disorder Evid. Based Ment. Health, February 1, 2004; 7(1): 17 - 17. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us